

31st January, 2025

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)- Extension of timeline communicated for sale of Company’s Unit situated at Thane

Dear Sir/Madam,

This is with reference to our intimation dated 30th July, 2024, whereby we had informed the Stock Exchanges about the decision to sell a decommissioned unit of the Company comprising of a plot of land and factory premises situated at A-159, MIDC, Wagle Industrial Estate, Thane West – 400604 and execution of a Memorandum of Understanding (“MOU”) with Sankalpan Architects Private Limited, (“Potential Buyer”).

We hereby inform that as certain conditions outlined in the MOU remain to be fulfilled by the Potential Buyer, the estimated timeline for completion of the abovementioned sale stands extended indefinitely. The Company may also evaluate other alternatives with respect to this unit.

We reiterate that the unit being decommissioned, the above matters have no impact on the operations of the Company.

The above information will also be available on the website of the Company www.piramalpharma.com.

Kindly take the above on record and oblige.

Yours truly,
For Piramal Pharma Limited

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India
T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

piramalpharma.com